Bronchogen Peptide: Studies in Relation to Bronchial Cells and Associated Systems

Bronchogen is a research peptide made of the amino acids Ala-Glu-Asp-Leu (AEDL). This tetrapeptide is classified as a bioregulator, similar to other members of the Khavinson peptides. It has been synthesized based on polypeptide sequences from murine bronchial mucosa and appears to stimulate reparative processes within the bronchial cell cultures.

The mechanisms behind such observations are posited to involve DNA stabilization, modifications of chromatin structure, affection of gene expression and transcription, and influencing epigenetic regulation. Below, we discuss the specific mechanisms and genes apparently affected by Bronchogen peptide, as well as the observations related to the peptide and bronchial epithelial cell cultures.

 

Latest Research on Bronchogen Peptide

Bronchogen Peptide and DNA

Bronchogen peptide is posited to support DNA stability and modify the expression of different genes contained in its structure. For example, one study investigated how the peptide Bronchogen may affect the thermostability of DNA using differential scanning microcalorimetry. Results suggested that it may have increased the DNA melting temperature by 3.1° C. The melting temperature of DNA is a measure of its thermostability, which reflects how much heat is needed to denature or “melt” the double-stranded DNA into single strands. Therefore, Bronchogen appears to act as a DNA-stabilizing ligand. ⁽¹⁾

According to research conducted by scientists, Bronchogen peptide is hypothesized to interact selectively with DNA, suggesting a preference for nucleotide sequences containing CTG motifs (cytosine (C), thymine (T), and guanine (G)). This selective binding suggests that Bronchogen recognizes specific features in the DNA sequence, possibly influencing the local structure of the double helix. Such interactions may induce localized conformational changes in the DNA, which might affect gene expression by altering how genetic information is accessed and regulated.

Bronchogen peptide might distinguish between different DNA methylation patterns, which may further modulate its interaction with specific sequences. Methylation, a common epigenetic modification where a methyl group is added to cytosine residues in DNA, often occurs at sites like CTG, and this pattern recognition may influence how Bronchogen regulates gene activity. This suggests a potential role for Bronchogen in epigenetic regulation, where it modulates gene expression based on both sequence and methylation status. ⁽²⁾

Bronchogen Peptide and Chromatin

Furthermore, Bronchogen peptide appears to interact with core histones—H1, H2B, H3, and H4—which are proteins involved in the packaging of DNA into chromatin. This suggests that Bronchogen might modify chromatin structure, potentially affecting gene accessibility and transcription by controlling how tightly or loosely DNA is wound around these histones. Bronchogens also seems to influence the activity of endonucleases, enzymes that cleave DNA strands. Its potential action on these enzymes may vary depending on the methylation status of the DNA, meaning whether chemical methyl groups are attached to specific regions of the DNA, which typically repress gene activity. This indicates a potential role for Bronchogen in epigenetic regulation—modifying gene expression without altering the DNA sequence—particularly in genes relevant to bronchial epithelial cell function. ⁽³⁾

Bronchogen and Bronchial Cells: Gene Expression

The research on Bronchogen peptide highlights its biological activity, focusing on its potential interaction with DNA and possible regulatory roles in bronchopulmonary models. As noted, while Bronchogen appears to interact with the nitrogenous bases of DNA, it does not appear to disrupt its structural integrity. Specifically, the researchers report “a possible interaction of the AEDL peptide with DNA in the major furrow at the guanine N7 site without a visible distortion of the double helix structure.” Consequently, studies in murine models of bronchial cell pathologies report that the peptide appears to help normalize cellular structures in bronchial tissue.

This action is thought to arise from Bronchogen’s potential to influence gene expression and protein synthesis, particularly in bronchial epithelial cells, which line the airways of the lungs.  Bronchogen peptide has been suggested to potentially increase the production of key proteins such as Ki67 (a marker for cell proliferation), Mcl-1 (an anti-apoptotic protein), and p53 (a tumor suppressor involved in cell cycle regulation). Additionally, it may support the function of bronchial epithelial cells by upregulating proteins like CD79 (involved in immune cell signaling) and NOS-3 (nitric oxide synthase, which plays a role in vascular function and inflammation).

The peptide also appears to activate several genes associated with the differentiation of bronchial epithelial cells, including Nkx2.1, SCGB1A1, SCGB3A2, FoxA1, and FoxA2, which are deemed critical for lung development and function. Furthermore, Bronchogen peptide may increase the expression of genes like MUC4 and MUC5AC, which are associated with mucus production in different respiratory disease models. ⁽⁴⁾

Bronchogen and Bronchial Cells: Cellular Aging

Bronchogen peptide appears to regulate the differentiation of bronchial epithelial cells. In murine models, models exposed to the peptide have indicated its potential to reduce inflammation, particularly in instances of bleomycin-induced pulmonary fibrosis. In such cases, it may decrease fibrotic changes, supporting both the structural integrity and function of the lungs. Underlying mechanisms likely involve its impact on gene expression, notably the regulation of specific transcription factors.

Studies in cultured bronchial epithelial cells indicate that Bronchogen peptide may support the expression of a transcription factor called Hoxa3. This potential action was noted in cell cultures from young, mature, and aged laboratory populations, with an increase in Hoxa3 levels by approximately 1.4 to 1.7 times compared to control groups. Exposure to Bronchogen may promote tissue differentiation through Hoxa3, which is involved in developmental processes. In contrast, Bronchogen does not seem to influence the expression of CXCL12, another gene associated with cell signaling and repair processes. This selective potential action implies that Bronchogen’s action may be limited to certain transcription factors, like Hoxa3, while sparing others, such as CXCL12, within bronchial epithelial cells.

Given that differentiation factors tend to decline in aging cell populations, Bronchogen peptide may hold potential as a regulatory agent capable of counteracting this decline. Indeed, the researchers concluded that the “inducing [impact] of peptides on the expression of differentiation factors was more pronounced in aged cultures, which [may] serve as a mechanism of their geroprotective [impact].”⁽⁵⁾

Bronchogen and Bronchial Cells: Integrity and Function

Bronchogen peptide has been suggested to play a role in the structural and functional remodeling and integrity of the bronchial epithelium, particularly in experimental chronic obstructive pulmonary disease (COPD) murine models. It may achieve this by engaging the regenerative abilities of local progenitor cells, such as Clara cells (now called club cells), basal cells, and possibly a subtype of type 2 alveolar cells. These progenitor cells are considered essential for maintaining the integrity of the bronchial lining and for initiating repair processes following injury.

The potential mechanism of Bronchogen peptide might involve influencing signal transduction pathways and transcription factors at the DNA level, potentially reprogramming these cells to promote cell proliferation and restore function. By stimulating progenitor cells, Bronchogen may support the repair of epithelial structures that COPD-related stressors, such as chronic inflammation and oxidative damage have damaged. In the study, animals treated with Bronchogen suggested reductions in the typical pathological changes seen in COPD. These changes were posited to include an apparent decrease in goblet cell hyperplasia, a condition where an excess of mucus-producing goblet cells forms, disrupting the balance between these cells and ciliated cells, which are responsible for moving mucus out of the lungs. This imbalance may impair mucociliary clearance, a crucial defense mechanism in the respiratory tract.

Bronchogen may have also reduced squamous metaplasia, a transformation of the bronchial epithelium that may predispose the tissue to cancerous changes, as well as a reduction in emphysematous areas—regions of the lung that have lost their elasticity and become hyperinflated, a hallmark of COPD. On a cellular level, Bronchogen was posited to alter the inflammatory environment within the lungs, as observed in the bronchoalveolar lavage fluid (BALF). It appeared to reduce the number of neutrophils, which are commonly elevated in COPD and contribute to lung damage by releasing destructive enzymes like neutrophil elastase.

Bronchogen may have, in some research contexts, contributed to the restoration of macrophage levels to those seen in functional lungs, indicating a shift away from the neutrophil-dominant inflammation typical of COPD toward a more regulated, less damaging immune response. Additionally, Bronchogen appeared to normalize the levels of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-8 (IL-8), which are key drivers of inflammation in COPD. This suggests a broader potential anti-inflammatory action.

The peptide also seemed to support local immune defenses, as indicated by an increase in secretory immunoglobulin A (sIgA) levels in the BALF. sIgA is widely considered critical for protecting the bronchial epithelium from pathogens and maintaining the integrity of the mucosal immune barrier. Its recovery may reflect supported epithelial function following Bronchogen peptide exposure. The peptide’s ability to restore immune function may be tied to its protection of the ciliary apparatus and correction of imbalances in epithelial cell populations, which appear vital for maintaining a functional respiratory epithelium.⁽⁶⁾ Further research also reported increased concentrations of surfactant protein B, which may support alveolar stability by reducing surface tension, indicating potential support for lung function.⁽⁷⁾

 
NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

 

References:

1. Monaselidze, J. R., Khavinson, V. K.h, Gorgoshidze, M. Z., Khachidze, D. G., Lomidze, E. M., Jokhadze, T. A., & Lezhava, T. A. (2011). Effect of the peptide Bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bulletin of experimental biology and medicine, 150(3), 375–377. https://doi.org/10.1007/s10517-011-1146-x
2. Fedoreyeva, L. I., Kireev, I. I., Khavinson, V. K.h, & Vanyushin, B. F. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry. Biokhimiia, 76(11), 1210–1219. https://doi.org/10.1134/S0006297911110022
3. Khavinson, V. K., Popovich, I. G., Linkova, N. S., Mironova, E. S., & Ilina, A. R. (2021). Peptide Regulation of Gene Expression: A Systematic Review. Molecules (Basel, Switzerland), 26(22), 7053. https://doi.org/10.3390/molecules26227053
4. Morozova, E. A., Lin’kova, N. S., Khavinson, V. K., Soloviev, A. Y., & Kasyanenko, N. A. (2017). In vitro interaction of the AEDL peptide with DNA. Journal of Structural Chemistry, 58, 420-424.
5. Khavinson, V. K.h, Linkova, N. S., Polyakova, V. O., Kheifets, O. V., Tarnovskaya, S. I., & Kvetnoy, I. M. (2012). Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of experimental biology and medicine, 153(1), 148–151. https://doi.org/10.1007/s10517-012-1664-1
6. Kuzubova, N. A., Lebedeva, E. S., Dvorakovskaya, I. V., Surkova, E. A., Platonova, I. S., & Titova, O. N. (2015). Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. Bulletin of experimental biology and medicine, 159(5), 685–688. https://doi.org/10.1007/s10517-015-3047-x
7. Titova, O. N., Kuzubova, N. A., Lebedeva, E. S., Preobrazhenskaya, T. N., Surkova, E. A., & Dvorakovskaya, I. V. (2017). Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova, 103(2), 201–208.